author-photo

Thierry Facon

University of Pennsylvania

10

Papers

939

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (533)
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (59)
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (12)
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

2014 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

2013 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (23)
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (215)
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: Evidence for a role of hepatocyte growth factor

2004 Leukemia
Show All
- Source
- Cite
- Save
Citations (70)
Very low incidence of p53 antibodies in adult non‐Hodgkin's lymphoma and multiple myeloma

1998 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (3)